-
Feb 16, 2024 Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
-
Aug 9, 2023 Voluntary Recall of seven ( 7 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard)
-
Aug 9, 2023 Voluntary Recall of three ( 3 ) lots of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP)
-
Apr 3, 2023 SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals
-
Feb 1, 2023 Voluntary Recall of one ( 1 ) lot of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg - Lot PY1904
-
Dec 16, 2022 Accessa becomes the patient support program manager for Apotex Inc.'s Apo-Deferasirox™ and Apo-Deferasirox (Type J)™ products.
-
Sep 28, 2022 SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals
-
Jul 27, 2022 Voluntary Recall of four ( 4 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg
-
Jul 20, 2022 First Generic Alternative to Eliquis® Now Available in Canada
-
May 17, 2022 Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis
-
Apr 26, 2022 Voluntary Recall of five ( 5 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg.
-
Jan 19, 2022 Voluntary Recall of one ( 1 ) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot PY1832.
-
Nov 30, 2021 Canada-Wide Contest Recognizes the Impact of Pharmacy Professionals on Patient Care
-
Nov 9, 2021 Patient Access to Affordable Cancer Treatment Increases with the Launch of New Biosimilar in Canada
-
Sep 30, 2021 VOLUNTARY NATIONWIDE RECALL: ONE LOT OF Mirvala™ 28 (Desogestrel and Ethinyl Estradiol Tablets, USP) 0.150 mg / 0.030 mg DUE TO POSSIBILITY OF ONE PLACEBO PILL IN PLACE OF AN ACTIVE PILL
-
Sep 27, 2021 Canadian Cancer Patients Have New Affordable Treatment Option
-
Sep 1, 2021 CANADIAN-MADE GENERIC OPTION TO TREAT MULTIPLE MYELOMA NOW AVAILABLE
-
Apr 29, 2021 Voluntary Recall of one ( 1 ) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot PY1831.
-
Apr 15, 2021 GOVERNMENT OF CANADA AWARDS APOTEX INC. A SIGNIFICANT CONTRACT TO SUPPLY A SAFETY NET OF ADDITIONAL DEXAMETHASONE IN CANADA
-
Apr 13, 2021 Voluntary Recall of one ( 1 ) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot RF0410.
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 18, 2026
Apotex Health Corp. announces closing of upsized bought deal secondary offering
Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").
-
Sep 15, 2026
Apotex Health Corp. announces $750 million bought deal secondary offering
Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.